CA Patent

CA3177005A1 — Methods of treating allergic conjunctivitis

Assigned to Ocular Therapeutix Inc · Expires 2021-11-04 · 5y expired

What this patent protects

Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel. The insert is administered to a subject for the treatment of allergic conjunctivitis.

USPTO Abstract

Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel. The insert is administered to a subject for the treatment of allergic conjunctivitis.

Drugs covered by this patent

Patent Metadata

Patent number
CA3177005A1
Jurisdiction
CA
Classification
—
Expires
2021-11-04
Drug substance claim
No
Drug product claim
No
Assignee
Ocular Therapeutix Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.